CA Patent

CA2651089A1 — A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine

Assigned to Boehringer Ingelheim International GmbH · Expires 2007-11-15 · 19y expired

What this patent protects

The invention relates to polymorphic crystal modifications of 1-((4-methyl-quinazolin-2-yl)methyl)-3,7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, their production and their use for the preparation of a medicament.

USPTO Abstract

The invention relates to polymorphic crystal modifications of 1-((4-methyl-quinazolin-2-yl)methyl)-3,7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)xanthine, their production and their use for the preparation of a medicament.

Drugs covered by this patent

Patent Metadata

Patent number
CA2651089A1
Jurisdiction
CA
Classification
—
Expires
2007-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.